Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

N-Glycolyl GM3 cancer vaccine - Center of Molecular Immunology/Recombio

Next Previous
Drug Profile

N-Glycolyl GM3 cancer vaccine - Center of Molecular Immunology/Recombio

Alternative Names: CIMAVaxG vaccine; N-glicolil GM3/VSSP; N-Glycolyl GM3/Vssp vaccine; N-glycolyl therapeutic vaccine; N-GlycolylGM3/VSSP/Montanide-ISA-51-vaccine; NGcGM3/VSSP vaccine

Latest Information Update: 16 Apr 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Center of Molecular Immunology
  • Developer Center of Molecular Immunology; Recombio
  • Class AIDS vaccines; Cancer vaccines; Conjugate vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Breast cancer
  • Phase II Malignant melanoma

Most Recent Events

  • 16 Apr 2021 N-Glycolyl GM3 cancer vaccine is still in phase II trial for Malignant melanoma (Metastatic disease, Second-line therapy or greater) in Cuba (RPCEC00000223)
  • 16 Apr 2021 N-Glycolyl GM3 cancer vaccine is still in phase II/III trial for Breast cancer in Cuba (RPCEC00000070)
  • 13 Dec 2017 Center of Molecular Immunology plans a clinical trial in Non-small cell lung cancer (Combination with Nimotuzumab, Late-stage disease) in Cuba (SC) (RPCEC00000270)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top